Theresa LaVallee - Concepedia

Author

Theresa LaVallee

CASI Pharmaceuticals (United States)ORCID

Also Known As

T. LaVallee, T. M. LaVallee, Theresa LaVallee, Theresa M LaVallee, Theresa M. LaVallee

316

Publications

4.1K

Citations

H-Index

Concepts

All Affiliations

CASI Pharmaceuticals (United States)The University of Texas MD Anderson Cancer Center Parker Institute for Cancer Immunotherapy University of California, San Francisco Massachusetts General Hospital

About

Theresa LaVallee is an author at CASI Pharmaceuticals (United States) specializing in medicine, pharmacology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	22	2.5K
2	Natural Sciences	2	2	86
3	Biochemistry	2	2	86
4	Engineering	1	1	29
5	Social Sciences	1	1	20

Theresa LaVallee

Publications

Citations

H-Index

Page 1

	Year	Citations
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF Nicola J. Mabjeesh, Daniel Escuín, Theresa LaVallee, Cancer Cell Tumor BiologyAngiogenesisMedicineVascular BiologyInhibits Tumor Growth	2003	726
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial Lacey Padrón, Deena M. Maurer, Mark H. O’Hara, Nature Medicine Randomized Phase 2Pancreatic CancerGastrointestinal OncologyMedicineImmunologic Analyses	2022	316
Effects of Aging and Hypoxia-Inducible Factor-1 Activity on Angiogenic Cell Mobilization and Recovery of Perfusion After Limb Ischemia Marta Bosch‐Marcé, Hiroaki Okuyama, Jacob Wesley, Circulation Research	2007	289
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study Mark H. O’Hara, Eileen M. O’Reilly, Gauri R. Varadhachary, The Lancet Oncology Phase 1BPancreatic CancerMetastatic Pancreatic AdenocarcinomaMedicineImmunology	2020	286
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce Harriet M. Kluger, Hussein A. Tawbi, Maria Libera Ascierto, Journal for ImmunoTherapy of Cancer New AgentsImmunologyImmunoeditingImmunotherapyTumor Resistance	2020	260
2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Theresa LaVallee, Xiaoguo H. Zhan, Chris J Herbstritt, PubMed Estradiol MetabolitesChemoprevention StrategyGynecologyCell DeathFemale Reproductive Function	2002	205
2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Theresa LaVallee, Xiaoguo H. Zhan, Michelle S. Johnson, PubMed Chemoprevention StrategyApoptosisGynecologyCell DeathTumor Biology	2003	142
Activation of the MAP Kinase Pathway by FGF-1 Correlates with Cell Proliferation Induction While Activation of the Src Pathway Correlates with Migration Theresa LaVallee, Igor Prudovsky, Grainne A. McMahon, The Journal of Cell Biology	1998	129
Hallmarks of Resistance to Immune-Checkpoint Inhibitors Maria Karasarides, Alexandria P. Cogdill, Paul B. Robbins, Cancer Immunology Research	2022	120
S100A13 Is Involved in the Regulation of Fibroblast Growth Factor-1 and p40 Synaptotagmin-1 Release in Vitro Carla Mouta Carreira, Theresa LaVallee, Francesca Tarantini, Journal of Biological Chemistry	1998	118

Page 1